Intellectual Property Watch is a non-profit independent news service reporting on international IP policymaking. The leading international news service on global policymaking, trends & debates on IP, innovation & creativity.
The decision is a year away, but there has been buzz for months around who might run in the election to be the next director general of the World Intellectual Property Organization. Intellectual Property Watch shares with you some of the names we've heard in the early going, completely unofficially and in no way intended to be exhaustive.
With the final vote over Europe's new copyright directive being expected during the Parliament’s March 26th session in Strasbourg, two decades of the copyright wars seem to culminate in another hot battle. Thousands of citizens have taken to the streets during recent weeks warning that the intended changes to liability fundamentally change how citizens can use social media platforms in the future. Article 13 will make providers liable for any copyright violation, pushing them to automatically filter content uploaded by their users. Article 11, the so-called snippet law or link tax, has been pushed for by large publishers in order to compel Google and the likes to share their revenues. Amidst the ongoing fight, Reto Hilty, Director of the Max Planck Institute for Innovation and Competition (MPI) in Munich, took a cool, analytic look into the two most debated provisions and concludes that the reform–even after a number of amendments - misses on what it originally set out to achieve: adapting copyright to digital times. [Note: this interview by IP-Watch writer Monika Ermert first appeared in German in heise online, hereheise online, here.]
The World Intellectual Property Organization received a record 3,447 domain name dispute cases from trademark owners in 2018 – up 12 percent from the previous year. In addition, there was a 15 percent increase in alternative dispute resolution cases, according to WIPO.
The European Patent Office continued its seemingly inexorable rise in patent applications, with almost all of its top 20 source countries showing growth in 2018. Nearly half of applications came from Europe, while the United States filed a record number and accounted for one-quarter of all applications, with a 2.7 percent increase over the previous year. Other countries saw significantly higher increases, though China’s rate of increase slowed, and Switzerland far and away filed the most patent applications per capita. Another notable statistic: the number of European patents granted rose 21 percent.
The 2019 Medicines for Europe Legal Affairs Conference will take place, for the first time, in Amsterdam. In its 15th edition, this conference will provide participants with the opportunity to exchange views and share ideas with leading industry executives and experts, counsel and European institution officials around the latest developments in intellectual property and legal affairs concerning generic, biosimilar and value added medicines within Europe and worldwide.
A cohort of senior Chinese officials from the China National Intellectual Property Administration (CNIPA) has graduated from a four-month training programme at the Intellectual Property Research Institute of Queen Mary University of London.
Chris Holly is a practicing intellectual property lawyer with extensive experience helping clients leverage IP portfolios in the agriculture, food, microbiology and biotechnology industries.Â Intellectual Property Watch's David Branigan interviewed Holly to gain his perspective on the technological, regulatory and intellectual property considerations of next generation plant breeding techniques, in particular those that involve gene editing usingÂ CRISPRÂ technology.
Fifa Rahman writes: The global health world, particularly as concerns skyrocketing drug prices and patent abuse, is in a unique space in time. Recently, the Office of the United States Trade Representative (USTR) has been carrying on as per usual. It has threatened the Malaysian and Colombian governments at numerous junctures to prevent them from issuing compulsory licences â€“ a completely legal mechanism which the US uses regularly - to access generic hepatitis C drugs. The Trump Administration has sent delegations to global health agencies in Geneva to intimidate them into reducing, or hiding, work on TRIPS flexibilities and fairer drug pricing.
Ubi Jus Ibi Remedium. Alas, that longstanding legal principle â€“ where thereâ€™s a right, thereâ€™s a remedy â€“ doesnâ€™t apply to IP owners in the US. Thanks to several Supreme Court rulings interpreting the US Constitution, owners of patents have no recourse when their IP is infringed by US states. Copyright owners now face the same fate, unless the Supreme Court reverses a recent 4th Circuit decision.